27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
A significant drug-placebo difference on the ADAS-Cog12 favoring GV-971 was present at each measurement time point, measurable at the week 4 visit and continuing throughout the trial. 3 key findings →
Design: clinical trial Participants: 818 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Vascular cognitive impairment without dementia is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it. 4 key findings →
Participants: 281 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sleep management might serve as a promising target for dementia prevention. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our findings showed significant associations between hearing and vision impairments and increased risks of all-cause and cause-specific dementia. 5 key findings →
Design: meta-analysis Participants: 937,908 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The mean age was 70.9 years (standard deviation, 5.9), 57.2% were women, 40.6% were illiterate, and 88.3% were farmers. 2 key findings →
Participants: 5,765 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
China bears a heavy burden of AD costs, which greatly change the estimates of AD cost worldwide. 2 key findings →
Participants: 3,098 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Given the inconsistent evidence regarding hearing aid use and reduced dementia risk, this study evaluates whether hearing aid use, particularly effective use, is associated with lower probable dementia risk among hearing-impaired older adults. 2 key findings →
Design: cohort Participants: 61,089 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Reducing the risk of dementia can halt the worldwide increase of affected people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Whether the association of cardiovascular diseases (CVDs) with dementia differs by sex remains unclear, and the role of socioeconomic, lifestyle, genetic, and medical factors in their association is unknown. 4 key findings →
Design: cohort study Participants: 502,649 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Overall age-adjusted and sex-adjusted prevalence was estimated to be 6·0% (95% CI 5·8-6·3) for dementia, 3·9% (3·8-4·1) for Alzheimer's disease, 1·6% (1·5-1·7) for vascular dementia, and 0·5% (0·5-0·6) for other dementias. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Per 1-m/s increase in ePWV was associated with an adjusted hazard ratio (HR) (95% confidence interval [CI]) of 1.51(1.30-1.75) for dementia and 1.58(1.33-1.89) for Alzheimer's disease (AD), and with an MMSE score decline (adjusted β-coefficient = -0.36; 95% CI = -0.52 to -0.21). 5 key findings →
Design: longitudinal study Participants: 1,857 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
However, the effect sizes were small. 1 key finding →
Participants: 34 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During the 4-year follow-up, 134 individuals were diagnosed with dementia. 5 key findings →
Design: cohort study Participants: 2,220 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A decreasing linear trend was observed between higher levels of curry consumption and cognitive decline (p = 0.037). 4 key findings →
Design: cohort study Participants: 2,920 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants with more FTUs were found to have a slower biological ageing process. 5 key findings →
Participants: 22,900 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The estimated total annual costs of dementia in China increased from 0.9 billion United States dollars (US$) in 1990 to US$ 47.2 billion in 2010 and were predicted to reach US$ 69.0 billion in 2020 and US$ 114.2 billion in 2030. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Vestibular disorders were linked to higher risks of all‐cause dementia (HR 1.86 and 95% CI 1.04–3.30), Alzheimer's disease (AD, 2.36, and 1.01–5.51), and vascular dementia (VD, 3.35, and 1.48–7.59). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results indicated that residence location, alcohol consumption, life satisfaction, depressive symptoms, and education level are key factors influencing the risk of MCI among older adults with functional disability. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) are known to increase the risk of developing Alzheimer disease and Parkinson's disease (PD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Triggering receptor expressed on myeloid cells-2 (TREM2) was a newly identified receptor expressed on microglia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High Resolution Image Download MS PowerPoint Slide Responders (R) and Non-Responders (NR) to lymphatic-venous anastomosis (LVA) surgery for relief of cognitive impairment show significant difference in their p-tau181/Aβ42 ratios via enzyme-linked immunosorbent assay (ELISA) of their cerebrospinal fluid (CSF). 3 key findings →
Participants: 43 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We aimed to determine whether genetically determined CRP was associated with hundreds of human phenotypes to guide anti-inflammatory interventions. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although the relationship between macroautophagy/autophagy and Alzheimer disease (AD) is widely studied, the underlying mechanisms are poorly understood, especially the regulatory role of the initiation signaling of autophagy on AD. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The MoCA score and the SCWT duration of the real group improved significantly compared with that of the sham group. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →